Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-09T16:21:50.441Z Has data issue: false hasContentIssue false

Chapter 43 - Hematopoietic Cell Transplants for Aggressive B-Cell Lymphomas

from Section 12 - Hematopoietic Cell Transplants for Lymphomas: Changing Indications

Published online by Cambridge University Press:  24 May 2017

By
Lori S. Muffly  and
Sonali M. Smith
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 417 - 427
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Sehn, LH, Berry, B, Chhanabhai, M, Fitzgerald, C, Gill, K, Hoskins, P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefGoogle Scholar
Philip, T, Guglielmi, C, Hagenbeek, A, Somers, R, Van der Lelie, H, Bron, D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. The New England Journal of Medicine. 1995;333(23):1540–5.CrossRefGoogle ScholarPubMed
Gisselbrecht, C, Glass, B, Mounier, N, Singh Gill, D, Linch, DC, Trneny, M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(27):4184–90.CrossRefGoogle ScholarPubMed
Gisselbrecht, C, Schmitz, N, Mounier, N, Ma, D, Trneny, M, Hagberg, H, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood. 2007;110(Abstract 517).CrossRefGoogle Scholar
Crump, M, Kuruvilla, J, Couban, S, MacDonald, DA, Kukreti, V, Kouroukis, CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014;32(31):3490–6.CrossRefGoogle ScholarPubMed
Van Imhoff, GW, McMillan, A, Matasar, MJ, Radford, J, Ardeshna, KM, Kuliczkowski, L, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928) Blood. 2014;124(630 abstract).CrossRefGoogle Scholar
Hamadani, M, Hari, PN, Zhang, Y, Carreras, J, Akpek, G, Aljurf, MD, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(11):1729−36.CrossRefGoogle Scholar
Kansara, RR, Savage, KJ, Villa, D, Shenkier, T, Gerrie, AS, Klasa, R, et al. Outcome in unselected patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) following R-CHOP when stem cell transplantation is not feasible. Blood. 2014;124(Abstract 3069).CrossRefGoogle Scholar
Colosia, A, Njue, A, Trask, PC, Olivares, R, Khan, S, Abbe, A, et al. Clinical efficacy and safety in relapsed/refractory diffuse large b-cell lymphoma: a systematic literature review. Clinical Lymphoma, Myeloma & Leukemia. 2014;14(5):343–55 e6.CrossRefGoogle ScholarPubMed
Gisselbrecht, C, Lepage, E, Molina, T, Quesnel, B, Fillet, G, Lederlin, P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002;20(10):2472–9.CrossRefGoogle ScholarPubMed
Kaiser, U, Uebelacker, I, Abel, U, Birkmann, J, Trumper, L, Schmalenberg, H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002;20(22):4413–9.CrossRefGoogle ScholarPubMed
Martelli, M, Gherlinzoni, F, De Renzo, A, Zinzani, PL, De Vivo, A, Cantonetti, M, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian multicenter randomized trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21(7):1255–62.CrossRefGoogle ScholarPubMed
Haioun, C, Lepage, E, Gisselbrecht, C, Bastion, Y, Coiffier, B, Brice, P, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87-2. Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1997;15(3):1131–7.CrossRefGoogle ScholarPubMed
Haioun, C, Lepage, E, Gisselbrecht, C, Salles, G, Coiffier, B, Brice, P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol–a groupe d’Etude des lymphomes de l’Adulte study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2000;18(16):3025−30.CrossRefGoogle ScholarPubMed
Milpied, N, Deconinck, E, Gaillard, F, Delwail, V, Foussard, C, Berthou, C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. The New England Journal of Medicine. 2004;350(13):1287–95.CrossRefGoogle ScholarPubMed
Greb, A, Bohlius, J, Trelle, S, Schiefer, D, De Souza, CA, Gisselbrecht, C, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treatment Reviews. 2007;33(4):338–46.CrossRefGoogle ScholarPubMed
Vitolo, U, Liberati, AM, Cabras, MG, Federico, M, Angelucci, E, Baldini, L, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial. Haematologica. 2005;90(6):793–801.Google ScholarPubMed
Betticher, DC, Martinelli, G, Radford, JA, Kaufmann, M, Dyer, MJ, Kaiser, U, et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2006;17(10):1546–52.CrossRefGoogle ScholarPubMed
Stiff, PJ, Unger, JM, Cook, JR, Constine, LS, Couban, S, Stewart, DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. The New England Journal of Medicine. 2013;369(18):1681–90.CrossRefGoogle ScholarPubMed
Oliansky, DM, Czuczman, M, Fisher, RI, Irwin, FD, Lazarus, HM, Omel, J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2011;17(1):20–47 e30.CrossRefGoogle ScholarPubMed
McCarthy, PL Jr., Hahn, T, Hassebroek, A, Bredeson, C, Gajewski, J, Hale, G, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(7):1116–23.CrossRefGoogle ScholarPubMed
Kim, JE, Lee, DH, Yoo, C, Kim, S, Kim, SW, Lee, JS, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leukemia Research. 2011;35(2):183–7.CrossRefGoogle ScholarPubMed
Shimoni, A, Avivi, I, Rowe, JM, Yeshurun, M, Levi, I, Or, R, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118(19):4706−14.CrossRefGoogle ScholarPubMed
Vose, JM, Carter, S, Burns, LJ, Ayala, E, Press, OW, Moskowitz, CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(13):1662–8.CrossRefGoogle ScholarPubMed
Winter, JN, Inwards, DJ, Spies, S, Wiseman, G, Patton, D, Erwin, W, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009;27(10):1653–9.CrossRefGoogle ScholarPubMed
Gisselbrecht, C, Schmitz, N, Mounier, N, Singh Gill, D, Linch, DC, Trneny, M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(36):4462–9.CrossRefGoogle Scholar
Bolanos-Meade, J, Garrett-Mayer, E, Luznik, L, Anders, V, Webb, J, Fuchs, EJ, et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2007;13(10):1185–91.CrossRefGoogle ScholarPubMed
Thompson, JA, Fisher, RI, Leblanc, M, Forman, SJ, Press, OW, Unger, JM, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 2008;111(8):4048–54.CrossRefGoogle Scholar
Armand, P, Nagler, A, Weller, EA, Devine, SM, Avigan, DE, Chen, YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(33):4199−206.CrossRefGoogle ScholarPubMed
van Besien, KW, de Lima, M, Giralt, SA, Moore, DF Jr., Khouri, IF, Rondon, G, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation. 1997;19(10):977–82.CrossRefGoogle ScholarPubMed
Bishop, MR, Dean, RM, Steinberg, SM, Odom, J, Pavletic, SZ, Chow, C, et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2008;19(11):1935–40.CrossRefGoogle ScholarPubMed
Rigacci, L, Puccini, B, Dodero, A, Iacopino, P, Castagna, L, Bramanti, S, et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Annals of Hematology. 2012;91(6):931−9.CrossRefGoogle ScholarPubMed
van Kampen, RJ, Canals, C, Schouten, HC, Nagler, A, Thomson, KJ, Vernant, JP, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(10):1342–8.CrossRefGoogle Scholar
Freytes, CO, Loberiza, FR, Rizzo, JD, Bashey, A, Bredeson, CN, Cairo, MS, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004;104(12):3797–803.CrossRefGoogle ScholarPubMed
Freytes, CO, Zhang, MJ, Carreras, J, Burns, LJ, Gale, RP, Isola, L, et al. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(8):1255–64.CrossRefGoogle ScholarPubMed
Peniket, AJ, Ruiz de Elvira, MC, Taghipour, G, Cordonnier, C, Gluckman, E, de Witte, T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplantation. 2003;31(8):667–78.CrossRefGoogle ScholarPubMed
Lazarus, HM, Zhang, MJ, Carreras, J, Hayes-Lattin, BM, Ataergin, AS, Bitran, JD, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2010;16(1):35–45.CrossRefGoogle ScholarPubMed
Glass, B, Hasenkamp, J, Wulf, G, Dreger, P, Pfreundschuh, M, Gramatzki, M, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. The Lancet Oncology. 2014;15(7):757−66.CrossRefGoogle Scholar
Bacher, U, Klyuchnikov, E, Le-Rademacher, J, Carreras, J, Armand, P, Bishop, MR, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62.CrossRefGoogle ScholarPubMed
Klyuchnikov, E, Bacher, U, Kroll, T, Shea, TC, Lazarus, HM, Bredeson, C, et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplantation. 2014;49(1):1–7.CrossRefGoogle Scholar
Rizzieri, DA, Johnson, JL, Byrd, JC, Lozanski, G, Blum, KA, Powell, BL, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. British Journal of Haematology. 2014;165(1):102–11.CrossRefGoogle ScholarPubMed
Hoelzer, D, Walewski, J, Dohner, H, Schmid, M, Hiddemann, W, Baumann, A, et al. Substantially improved outcome of adult Burkitt non-Hodgkin lymphoma and leukemia patients with rituximab and a short-intensive chemotherapy; report of a large prospective multicenter trial. ASH Annual Meeting Abstracts. 2012;120(21):667.Google Scholar
van Imhoff, GW, van der Holt, B, MacKenzie, MA, Ossenkoppele, GJ, Wijermans, PW, Kramer, MH, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia. 2005;19(6):945−52.CrossRefGoogle ScholarPubMed
Maramattom, LV, Hari, PN, Burns, LJ, Carreras, J, Arcese, W, Cairo, MS, et al. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(2):173–9.CrossRefGoogle ScholarPubMed
Johnson, NA, Slack, GW, Savage, KJ, Connors, JM, Ben-Neriah, S, Rogic, S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(28):3452–9.CrossRefGoogle ScholarPubMed
Oki, Y, Noorani, M, Lin, P, Davis, RE, Neelapu, SS, Ma, L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. British Journal of Haematology. 2014;166(6):891−901.CrossRefGoogle Scholar
Gandi, M, Petrich, AM, Cassaday, RD, Press, OW, Shah, K, Whyman, J, et al. Impact of induction regimen and consolidative stem cell transplantation in patients with double hit lymphoma (DHL): a large multicenter retrospective analysis. Blood. 2014;124(15):2354−61.Google Scholar
Petrich, AM, Gandhi, M, Jovanovic, B, Castillo, JJ, Rajguru, S, Yang, DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61.CrossRefGoogle ScholarPubMed
Oki, Y, Noorani, M, Lin, P, Davis, RE, Neelapu, SS, Ma, L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. British Journal of Haematology. 2014;166(6):891–901.CrossRefGoogle Scholar
Cuccuini, W, Briere, J, Mounier, N, Voelker, HU, Rosenwald, A, Sundstrom, C, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012;119(20):4619−24.CrossRefGoogle ScholarPubMed
Al-Tourah, AJ, Gill, KK, Chhanabhai, M, Hoskins, PJ, Klasa, RJ, Savage, KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(32):5165–9.CrossRefGoogle ScholarPubMed
Villa, D, Crump, M, Panzarella, T, Savage, KJ, Toze, CL, Stewart, DA, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(9):1164–71.CrossRefGoogle ScholarPubMed
Wirk, B, Fenske, TS, Hamadani, M, Zhang, MJ, Hu, ZH, Akpek, G, et al. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(7):951−9.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×